Cargando…
Comprehensive metabolomic characterization of atrial fibrillation
BACKGROUND: Using human humoral metabolomic profiling, we can discover the diagnostic biomarkers and pathogenesis of disease. The specific characterization of atrial fibrillation (AF) subtypes with metabolomics may facilitate effective and targeted treatment, especially in early stages. OBJECTIVES:...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9393302/ https://www.ncbi.nlm.nih.gov/pubmed/36003904 http://dx.doi.org/10.3389/fcvm.2022.911845 |
_version_ | 1784771242657579008 |
---|---|
author | Lu, Chengcan Liu, Chunyan Mei, Di Yu, Mengjie Bai, Jian Bao, Xue Wang, Min Fu, Kejia Yi, Xin Ge, Weihong Shen, Jizhong Peng, Yuzhu Xu, Wei |
author_facet | Lu, Chengcan Liu, Chunyan Mei, Di Yu, Mengjie Bai, Jian Bao, Xue Wang, Min Fu, Kejia Yi, Xin Ge, Weihong Shen, Jizhong Peng, Yuzhu Xu, Wei |
author_sort | Lu, Chengcan |
collection | PubMed |
description | BACKGROUND: Using human humoral metabolomic profiling, we can discover the diagnostic biomarkers and pathogenesis of disease. The specific characterization of atrial fibrillation (AF) subtypes with metabolomics may facilitate effective and targeted treatment, especially in early stages. OBJECTIVES: By investigating disturbed metabolic pathways, we could evaluate the diagnostic value of biomarkers based on metabolomics for different types of AF. METHODS: A cohort of 363 patients was enrolled and divided into a discovery and validation set. Patients underwent an electrocardiogram (ECG) for suspected AF. Groups were divided as follows: healthy individuals (Control), suspected AF (Sus-AF), first diagnosed AF (Fir-AF), paroxysmal AF (Par-AF), persistent AF (Per-AF), and AF causing a cardiogenic ischemic stroke (Car-AF). Serum metabolomic profiles were determined by gas chromatography–mass spectrometry (GC-MS) and liquid chromatography–quadrupole time-of-flight mass spectrometry (LC-QTOF-MS). Metabolomic variables were analyzed with clinical information to identify relevant diagnostic biomarkers. RESULTS: The metabolic disorders were characterized by 16 cross-comparisons. We focused on comparing all of the types of AF (All-AFs) plus Car-AF vs. Control, All-AFs vs. Car-AF, Par-AF vs. Control, and Par-AF vs. Per-AF. Then, 117 and 94 metabolites were identified by GC/MS and LC-QTOF-MS, respectively. The essential altered metabolic pathways during AF progression included D-glutamine and D-glutamate metabolism, glycerophospholipid metabolism, etc. For differential diagnosis, the area under the curve (AUC) of specific metabolomic biomarkers ranged from 0.8237 to 0.9890 during the discovery phase, and the predictive values in the validation cohort were 78.8–90.2%. CONCLUSIONS: Serum metabolomics is a powerful way to identify metabolic disturbances. Differences in small–molecule metabolites may serve as biomarkers for AF onset, progression, and differential diagnosis. |
format | Online Article Text |
id | pubmed-9393302 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-93933022022-08-23 Comprehensive metabolomic characterization of atrial fibrillation Lu, Chengcan Liu, Chunyan Mei, Di Yu, Mengjie Bai, Jian Bao, Xue Wang, Min Fu, Kejia Yi, Xin Ge, Weihong Shen, Jizhong Peng, Yuzhu Xu, Wei Front Cardiovasc Med Cardiovascular Medicine BACKGROUND: Using human humoral metabolomic profiling, we can discover the diagnostic biomarkers and pathogenesis of disease. The specific characterization of atrial fibrillation (AF) subtypes with metabolomics may facilitate effective and targeted treatment, especially in early stages. OBJECTIVES: By investigating disturbed metabolic pathways, we could evaluate the diagnostic value of biomarkers based on metabolomics for different types of AF. METHODS: A cohort of 363 patients was enrolled and divided into a discovery and validation set. Patients underwent an electrocardiogram (ECG) for suspected AF. Groups were divided as follows: healthy individuals (Control), suspected AF (Sus-AF), first diagnosed AF (Fir-AF), paroxysmal AF (Par-AF), persistent AF (Per-AF), and AF causing a cardiogenic ischemic stroke (Car-AF). Serum metabolomic profiles were determined by gas chromatography–mass spectrometry (GC-MS) and liquid chromatography–quadrupole time-of-flight mass spectrometry (LC-QTOF-MS). Metabolomic variables were analyzed with clinical information to identify relevant diagnostic biomarkers. RESULTS: The metabolic disorders were characterized by 16 cross-comparisons. We focused on comparing all of the types of AF (All-AFs) plus Car-AF vs. Control, All-AFs vs. Car-AF, Par-AF vs. Control, and Par-AF vs. Per-AF. Then, 117 and 94 metabolites were identified by GC/MS and LC-QTOF-MS, respectively. The essential altered metabolic pathways during AF progression included D-glutamine and D-glutamate metabolism, glycerophospholipid metabolism, etc. For differential diagnosis, the area under the curve (AUC) of specific metabolomic biomarkers ranged from 0.8237 to 0.9890 during the discovery phase, and the predictive values in the validation cohort were 78.8–90.2%. CONCLUSIONS: Serum metabolomics is a powerful way to identify metabolic disturbances. Differences in small–molecule metabolites may serve as biomarkers for AF onset, progression, and differential diagnosis. Frontiers Media S.A. 2022-08-08 /pmc/articles/PMC9393302/ /pubmed/36003904 http://dx.doi.org/10.3389/fcvm.2022.911845 Text en Copyright © 2022 Lu, Liu, Mei, Yu, Bai, Bao, Wang, Fu, Yi, Ge, Shen, Peng and Xu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Cardiovascular Medicine Lu, Chengcan Liu, Chunyan Mei, Di Yu, Mengjie Bai, Jian Bao, Xue Wang, Min Fu, Kejia Yi, Xin Ge, Weihong Shen, Jizhong Peng, Yuzhu Xu, Wei Comprehensive metabolomic characterization of atrial fibrillation |
title | Comprehensive metabolomic characterization of atrial fibrillation |
title_full | Comprehensive metabolomic characterization of atrial fibrillation |
title_fullStr | Comprehensive metabolomic characterization of atrial fibrillation |
title_full_unstemmed | Comprehensive metabolomic characterization of atrial fibrillation |
title_short | Comprehensive metabolomic characterization of atrial fibrillation |
title_sort | comprehensive metabolomic characterization of atrial fibrillation |
topic | Cardiovascular Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9393302/ https://www.ncbi.nlm.nih.gov/pubmed/36003904 http://dx.doi.org/10.3389/fcvm.2022.911845 |
work_keys_str_mv | AT luchengcan comprehensivemetabolomiccharacterizationofatrialfibrillation AT liuchunyan comprehensivemetabolomiccharacterizationofatrialfibrillation AT meidi comprehensivemetabolomiccharacterizationofatrialfibrillation AT yumengjie comprehensivemetabolomiccharacterizationofatrialfibrillation AT baijian comprehensivemetabolomiccharacterizationofatrialfibrillation AT baoxue comprehensivemetabolomiccharacterizationofatrialfibrillation AT wangmin comprehensivemetabolomiccharacterizationofatrialfibrillation AT fukejia comprehensivemetabolomiccharacterizationofatrialfibrillation AT yixin comprehensivemetabolomiccharacterizationofatrialfibrillation AT geweihong comprehensivemetabolomiccharacterizationofatrialfibrillation AT shenjizhong comprehensivemetabolomiccharacterizationofatrialfibrillation AT pengyuzhu comprehensivemetabolomiccharacterizationofatrialfibrillation AT xuwei comprehensivemetabolomiccharacterizationofatrialfibrillation |